K284-6111 是一种高亲和力且口服活性的 CHI3L1 抑制剂,可抑制 CHI3L1 的表达,并通过抑制 ERK 和 NF-κB 信号通路、p50 和 p65 的核转位以及 IκB 的磷酸化发挥作用;它通过减轻淀粉样生成和神经炎症改善记忆功能障碍,同时降低 iNOS、COX-2、GFAP 和 Iba-1 等炎症蛋白水平,还能减少类特应性皮炎的皮肤炎症并抑制 LPS (MS-X54539) 诱导的肝损伤,因此可用于阿尔茨海默症和脓毒症样肝损伤的研究。
产品编号: MS-X94481 纯度: 99.94% CAS No.: 702668-62-0 分子式: C30H37N3O4S 分子量: 535.70
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

K284-6111 是一种高亲和力且口服活性的 CHI3L1 抑制剂,可抑制 CHI3L1 的表达,并通过抑制 ERK 和 NF-κB 信号通路、p50 和 p65 的核转位以及 IκB 的磷酸化发挥作用;它通过减轻淀粉样生成和神经炎症改善记忆功能障碍,同时降低 iNOS、COX-2、GFAP 和 Iba-1 等炎症蛋白水平,还能减少类特应性皮炎的皮肤炎症并抑制 LPS (MS-X54539) 诱导的肝损伤,因此可用于阿尔茨海默症和脓毒症样肝损伤的研究。

生物实验数据

生物活性 K284-6111 is a high-affinity, orally active CHI3L1 inhibitor that suppresses CHI3L1 expression and acts by inhibiting the ERK and NF-κB signaling pathways, the nuclear translocation of p50 and p65, and the phosphorylation of IκB; it ameliorates memory dysfunction by alleviating amyloidogenesis and neuroinflammation while reducing the levels of inflammatory proteins such as iNOS, COX-2, GFAP, and Iba-1, and it also attenuates atopic dermatitis-like skin inflammation and inhibits LPS (MS-X54539)-induced liver injury, making it useful for research on Alzheimer's disease and sepsis-like liver injury.
体外研究
(In Vitro)

K284-6111 (0.5-2 μM, 24 h) 降低 Aβ 或 LPS (MS-X54539) 在 BV-2 细胞和星形胶质细胞中诱导的 NO 浓度。
K284-6111 (5 μM, 26 h) 降低 CHI3L1 过表达所引起的 BV-2 细胞的神经炎症。
K284-6111 (5 μM, 26 h) 抑制 Aβ 诱导的 BV-2 细胞中 PTX3 的表达。
K284-6111 (0.5-2 μM, 26 h) 阻止 LPS 刺激的 BV-2 细胞和星形胶质细胞中以及 TNF-α/IFN-γ 激活的 HaCaT 细胞的 p50 和 p65 的核转位。
K284-6111 (0.5-2 μM, 4-6 h) 抑制 TNF-α/IFN-γ 组合处理的 HaCaT 细胞中 CHI3L1、IL-1β、IL-4、IL-6 TSLP 和 LTF 的水平。
K284-6111 (2 μM, 6 days) 减轻特应性皮炎重建的人类皮肤 (RHS) 模型中的炎症。
K284-6111 (0.5-22 μM, 1 h) 降低 LPS 诱导的肝细胞中 CHI3L1、CXCL3 的表达以及细胞因子的释放。
K284-6111 (2 μg/mL, 25 h) 降低经人重组 CXCL3 和 LPS 处理的 THLE-2 细胞以及 CXCL3 敲除 THLE-2 细胞经 LPS 处理后的 IL-10 和 IL-4 水平。

Western Blot Analysis

Cell Line: Aβ-induced BV2 cells and CHI3L1 overexpressing BV-2 cells
Concentration: 5 μM
Incubation Time: 26 h
Result: Reduced Aβ-induced expression of inflammatory proteins such as iNOS, COX-2, and IBA-1.

Real Time qPCR

Cell Line: Aβ-induced BV2 cells and CHI3L1 overexpressing BV-2 cells
Concentration: 5 μM
Incubation Time: 26 h
Result: Reduced the mRNA expression level of pro-inflammatory cytokines such as Tnf, Il1b, Il6, and Cd86.

ELISA Assay

Cell Line: HaCaT cells treated with TNF-α/IFN-γ combination
Concentration: 0.5, 1, 2 μM
Incubation Time: 4 h
Result: Decreased the level of CHI3L1, IL-1β, IL-4, IL-6 and TSLP.

Western Blot Analysis

Cell Line: HaCaT cells treated with TNF-α/IFN-γ combination
Concentration: 0.5, 1, 2 μM
Incubation Time: 6 h
Result: Inhibited the nuclear translocation of p50 and p65 and p-IκBα.

Real Time qPCR

Cell Line: LPS-induced hepatic cells
Concentration: 0.5, 1, 2 μM
Incubation Time: 1 h
Result: Reduced the mRNA levels of M1 macrophage protein and cytokines (iNOS, CD86, TNF-α, and IL-6) and M2 macrophage cytokines (MRC1, Arg 1, IL-10, and IL-4).
体内研究
(In Vivo)

K284-6111 (3 mg/kg,灌胃给药,每天一次,持续四周) 缓解了Tg2576 AD 小鼠模型中的记忆障碍。
K284-6111 (3 mg/kg,灌胃给药,每日一次,4 周) 预防 Aβ1-42 灌注小鼠的记忆障碍。
K284-6111 (1-2 mg/mL (10-20 μg/cm2),局部给药,每周 3 次,4 周) 抑制 Phthalic anhydride (MS-D48598) 诱导的特应性皮炎。
K284-6111 (0.25-1 mg/kg,腹腔注射,每三天一次,持续 2 周) 对 LPS 诱导的肝损伤表现出保护作用。

Animal Model: Twelve-month-old Tg2576 mice
Dosage: 3 mg/kg
Administration: i.g. once daily for 4 weeks
Result: Increased the mean time spent in the target quadrant.
Showed higher an average step-through latency.
Inhibited the accumulation of Aβ in Tg2576 mouse brain.
Reduced the number of iNOS and COX-2-reactive cells.
Decreased the expression of GFAP, IBA-1, iNOS, and COX-2.
Decreased the expression levels of the markers M1 microglia (Tnf, Il1b, Il6, and Cd86).
Did not affect M2 microglia markers such as Arg1, Mrc1, Tgfb, and Il10.
Reduced the levels of p-IκBα, p-ERK1/2, and p-JNK.
Reduced the levels of PTX3.
Animal Model: Aggregated Aβ1-42 (300 pmol) was unilaterally infused into the brains of 8- to 10-week-old male ICR mice over 14 days
Dosage: 3 mg/kg
Administration: i.g. once daily for 4 weeks
Result: Showed a great reduction in escape latency on day 6.
Showed a shorter escape distance compared to Aβ1-42-infused mice.
Spent much more time in the quadrant zone.
Increased step-through latency.
Reduced the expression of CHI3L1, inflammatory proteins (iNOS and COX-2), and GFAP and Iba-1.
Decreased Aβ-induced mRNA levels of CHI3L1, TNF-α, IL-1β, and IL-6 in brain tissues.
Prevented amyloidogenesis and neuronal cell death in Aβ1-42-infused mice brain.
Decreased the expression of p50 p65 and p-IκBα.
Animal Model: C57BL/6J mice (8-week-old) applied with 5% Phthalic anhydride (PA) solution was spread on the back skin 3 times a week for 4 weeks
Dosage: 1 mg/mL and 2 mg/mL (10 μg or 20 μg/cm2)
Administration: Topical administration 3 times a week for 4 weeks
Result: Reduced epidermal thickness.
Reduced the number of infiltrating mast cells in the skin.
Decreased the serum IgE concentration.
Reduced the lymph node weight.
Reduced the levels of CHI3L1, IL-1β, IL-4, IL-6 and TSLP.
Reduced the mRNA expression of AD-related genes such as TNF-α, IL-1β, IL-4, IL-5, IL-6, IL-13, IL-31, IL-33, and CCL17.
Inhibited the nuclear translocation of p50 and p65 in a dose-dependent manner.
Reduced LTF expression in PA-induced skin tissues.
Animal Model: C57BL/6J mice (8-week-old) were injected with LPS (i.p., 30 mg/kg)
Dosage: 0.25, 0.5, 1 mg/kg
Administration: i.p. once every three days for 2 weeks
Result: Showed the induction of significant liver damage.
Reduced CHI3L1 expression and cytokine release (iNOS, COX-2) in LPS-induced liver injury.
性状 固体
颜色 White to off-white

化学信息

分子量 535.70
分子式 C30H37N3O4S
CAS No. 702668-62-0

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 2 mg/mL (3.73 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.8667 mL9.3336 mL18.6672 mL46.6679 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础